Due to limited information reported on the clinical characteristics and outcomes of Burkitt lymphoma (BL) patients with gastrointestinal (GI) involvement, here we used the Surveillance, Epidemiology, and End Results (SEER) database to perform our study in a population-based scale. Extranodal GI involvement was categorized into gastric and intestinal primary sites. A total of 477 BL patients with GI involvement extracted from the SEER database between 2004 and 2015 were included in this study, 112 (23.5%) with the stomach and 365 (76.5%) with the intestine. Our study demonstrated that gastric involvement, older age, male gender, black race, advanced-stage III/IV, no-chemotherapy, and earlier years of diagnosis were associated with a significantly worse overall survival (OS) in GI BL patients after adjustment in multivariate analysis, whereas marital status did not significantly influence OS. Notably, BL Patients with gastric involvement had a significantly inferior 5-year OS in both univariate and multivariate analysis, as compared to those with intestinal involvement (37.8% vs. 70.2%; Univariate: HR = 2.637, P < .001; Multivariate: HR = 1.489, P = .016). In subgroup analysis, we demonstrated that gastric BL patients had a consistently worse OS than intestinal patients regardless of gender, clinical stage and year of diagnosis. Hopefully, with the advances in modern therapy, improved survival has been found in BL patients with GI involvement as a whole, specifically those with gastric involvement (HR = 0.529, P = .011) in recent years of diagnosis. In conclusion, despite the improved survival achieved in recent years, the prognosis of BL patients with gastric involvement is still poor. Novel personalized therapies and better access to intensive care remain to be needed.

中文翻译：

---

胃肠道伯基特淋巴瘤患者胃受累的预后较差。

由于关于Burkitt淋巴瘤（BL）胃肠道（GI）患者的临床特征和结局的报道报道有限，因此在此我们使用监测，流行病学和最终结果（SEER）数据库以人群为基础进行研究。结外胃肠道受累分为胃和肠原发部位。从2004年至2015年从SEER数据库中提取的总共477例BL胃肠道受累患者被纳入本研究，其中112例（23.5％）患胃，365例（76.5％）患肠。我们的研究表明，GIBL患者经调整后，其胃部受累，年龄，男性，黑人，III / IV期晚期，无化学疗法和早期诊断与总生存期（OS）显着降低有关。多元分析 而婚姻状况并没有显着影响OS。值得注意的是，与肠胃受累的患者相比，胃受累的BL患者在单因素和多因素分析中的5年OS均显着较低（37.8％对70.2％;单因素：HR = 2.637，P <.001;多因素： HR = 1.489，P = .016）。在亚组分析中，我们证明了胃BL患者的OS始终比肠道患者差，无论性别，临床阶段和诊断年份如何。希望随着现代疗法的进步，在最近几年的诊断中，已发现整体上有胃肠道受累的BL患者，特别是有胃部受累的BL患者（HR = 0.529，P = .011），其生存期得到了改善。总之，尽管近年来生存率有所提高，BL胃受累患者的预后仍然较差。仍需要新颖的个性化疗法和更好的重症监护服务。